Revlimid and Amicar drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Revlimid (lenalidomide) and Amicar (aminocaproic acid). Common drug interactions include dyspnoea among females and anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Revlimid and Amicar. It is created by eHealthMe based on reports of 53 people who take the same drugs from the FDA, and is updated regularly.

What is Revlimid?

Revlimid has active ingredients of lenalidomide. It is often used in multiple myeloma. eHealthMe is studying from 378,026 Revlimid users. Check the latest studies of Revlimid.

What is Amicar?

Amicar has active ingredients of aminocaproic acid. eHealthMe is studying from 1,323 Amicar users. Check the latest studies of Amicar.

On Jul, 13, 2026

53 people who take Revlimid and Amicar together, and have interactions are studied.

What are the common drug interactions of Revlimid and Amicar, by gender? *:

female:

Dyspnoea (difficult or laboured respiration)
Full blood count decreased
Hodgkin's disease (cancer originating from white blood cells)
Neutropenia (an abnormally low number of neutrophils)
Thrombocytopenia (decrease of platelets in blood)
Disease progression
Bone disorder
Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Decreased immune responsiveness
Immune system disorder

male:

Anaemia (lack of blood)
Hypotension (abnormally low blood pressure)
Arthralgia (joint pain)
Atelectasis (partial or complete collapse of the lung)
Back disorder
Benign prostatic hyperplasia (benign enlargement of the prostate)
Bone disorder
Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries)
Calculus urethral (stone in urethra)
Cardiomegaly (increased size of heart than normal)

What are the common drug interactions of Revlimid and Amicar, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Pulmonary embolism (blockage of the main artery of the lung)
Respiratory distress (difficulty in breathing)
Hodgkin's disease (cancer originating from white blood cells)
Pneumonia
Loss of consciousness
Unresponsive to stimuli

30-39:

Respiratory distress (difficulty in breathing)
Sepsis (a severe blood infection that can lead to organ failure and death)

40-49:

n/a

50-59:

Total lung capacity decreased
Tumour invasion (starting of tumour)
Ventricular hypertrophy (enlargement of ventricles (lower chambers) in the heart)
Weight decreased
Swelling face
Gammopathy (abnormal proliferation of the lymphoid cells producing immunoglobulins)
Back pain
Cellulitis (infection under the skin)
Chest pain
Fall

60+:

Death
Anaemia (lack of blood)
Drug ineffective
Arrhythmia (irregular heartbeat)
Asthenia (weakness)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Cardiac failure
Dyspnoea (difficult or laboured respiration)
Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
Pain

What are the existing conditions these people have? *

Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 21 people, 39.62%
Pain: 8 people, 15.09%
Thrombocytopenia (decrease of platelets in blood): 4 people, 7.55%
Salivary Gland Infections: 3 people, 5.66%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 3 people, 5.66%
Hodgkin's Lymphoma (cancer originating from white blood cells): 3 people, 5.66%
Constipation: 3 people, 5.66%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 3 people, 5.66%

* Approximation only. Some reports may have incomplete information.

Do you take Revlimid and Amicar?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously